Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02952820
Other study ID # E2006-G000-303
Secondary ID 2015-001463-39
Status Completed
Phase Phase 3
First received
Last updated
Start date November 15, 2016
Est. completion date January 8, 2019

Study information

Verified date December 2017
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.


Description:

This is a long-term (approximately 1 year), multicenter, randomized, controlled, double-blind, parallel group study of two doses of lemborexant and placebo in approximately 900 male or female participants with insomnia disorder. Approximately 40% of participants will be age 65 years or older. The study will last a maximum of 60 weeks, and will include a Screening Period, an approximately 54-week Treatment Period (during which study medication will be administered), and a 2-week Follow-up Period. All participants will receive lemborexant for at least 6 months and will receive placebo at some point during the study. Participants will not know which medication they receive (lemborexant or placebo) until the study has been completed, and will not know the timings at which the medication will change.


Recruitment information / eligibility

Status Completed
Enrollment 971
Est. completion date January 8, 2019
Est. primary completion date January 8, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female, age 18 years or older at the time of informed consent

- Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder, as follows:

- Complains of dissatisfaction with nighttime sleep in the form of difficulty getting to sleep, difficulty staying asleep, and/or awakening earlier in the morning than desired despite adequate opportunity for sleep

- Frequency of complaint =3 times per week

- Duration of complaint =3 months

- Associated with complaint of daytime impairment

- History of (Subjective Sleep Onset Latency) sSOL =30 minutes on at least 3 nights per week in the previous 4 weeks and/or subjective Wake after Sleep Onset (sWASO) =60 minutes on at least 3 nights per week in the previous 4 weeks

- History of regular time spent in bed, either sleeping or trying to sleep, between 7 and 9 hours

- Regular bedtime, between 21:00 and 01:00 and regular wake time, the time the participant gets out of bed for the day, between 05:00 and 10:00

- Insomnia Severity Index (ISI) score =15

- Confirmation of current insomnia symptoms as determined from the Sleep Diary completed on at least 7 consecutive mornings (minimum 5 of 7 for eligibility), such that sSOL =30 minutes on at least 3 of the 7 nights and/or sWASO =60 minutes on at least 3 of the 7 nights

- Confirmation of time spent in bed, as determined from on the Sleep Diary completed on 7 mornings between the first and second screening visit, such that there are not more than 2 nights with duration of time spent in bed 7 hours and 10 hours

- Confirmation of regular bedtimes and wake times such that the participant has a regular time spent in bed, either sleeping or trying to sleep, between 7 and 10 hours for the final 7 nights of the before visit 3.

- Confirmation of regular bedtime between 21:00 and 01:00 and time of getting out of bed for the day between 05:00 and 10:00 for the final 7 nights of the before visit 3.

- Willing and able to comply with all aspects of the protocol, including staying in bed for at least 7 hours each night

- Willing to not start a behavioral or other treatment program for insomnia during the participants participation in the study

Exclusion Criteria:

- A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, or an exclusionary score on screening instruments to rule out individuals with symptoms of certain sleep disorders other than insomnia.

- STOPBang score greater than or equal to (>=) 5

- International Restless Legs Scale (IRLS) score >=16

- Epworth Sleepiness Scale (ESS) score >15

- Reports symptoms potentially related to narcolepsy that in the clinical opinion of the investigator indicates the need for referral for a diagnostic evaluation for the presence of narcolepsy

- Reports a history of sleep-related violent behavior, or sleep driving, or any other complex sleep-related behavior, eg, making phone calls, or preparing and eating food while asleep

- For participants who underwent polysomnography (PSG) within the previous year:

- Age 18 to 64 years: Apnea Hypopnea Index =10, or Periodic Limb Movements with Arousal Index =10

- Age =65 years: Apnea Hypopnea Index >15, or Periodic Limb Movements with Arousal Index >15

- Beck Depression Inventory - II (BDI II) score >19 at Screening

- Beck Anxiety Inventory (BAI) score >15 at Screening

- Habitually naps more than 3 times per week

- Females who are breastfeeding or pregnant at Screening or Study Baseline

- Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.)

- Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her participation in the study

- History of drug or alcohol dependency or abuse within approximately the previous 2 years

- Reports habitually consuming more than 14 drinks containing alcohol per week (females) or more than 21 drinks containing alcohol per week (males), or unwilling to limit alcohol intake to no more than 2 drinks per day or forego having alcohol within the 3 hours before bedtime for the duration of his/her participation in the study

- A prolonged QT/QT interval corrected by Fridericia's formula (QTcF >450 ms) as demonstrated by a repeated electro cardiogram(ECG) at Screening (repeated only if initial ECG indicates a QTcF interval >450 ms)

- Current evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, neurological [including participants who lack capacity and/or whose cognitive decline indicates disorientation to person/place/time and/or situation], or psychiatric disease or malignancy other than basal cell carcinoma) or chronic pain that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments

- Comorbid nocturia resulting in frequent need to get out of bed to use the bathroom during the night

- Scheduled for major surgery during the study

- Used any prohibited prescription or over-the-counter concomitant medications within 1 week before the first dose of study medication

- Used any modality of treatment for insomnia, including cognitive behavioral therapy or marijuana within 2 weeks before Screening

- Failed treatment with suvorexant (Belsomra®) (efficacy and/or safety) following treatment with an appropriate dose and of adequate duration in the opinion of the investigator

- Transmeridian travel across more than 3 time zones in the 2 weeks before Screening, or between Screening and Study Baseline

- Previously participated in any clinical trial of lemborexant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
lemborexant

Placebo


Locations

Country Name City State
Canada Facility # 1 Kelowna British Columbia
Canada Facility # 1 Point-Claire Quebec
Canada Facility # 1 Sherbrooke Quebec
Canada Facility # 1 Toronto Ontario
Finland Facility # 1 Helsinki
Finland Facility # 1 Kuopio
Finland Facility # 1 Oulu Oulun Laani
Finland Facility # 1 Tampere
Finland Facility # 1 Turku
Finland Facility # 2 Turku
Germany Facility # 1 Berlin
Germany Facility # 2 Berlin
Germany Facility # 3 Berlin
Germany Facility # 1 Bochum Nordrhein-Westfalen
Germany Facility # 1 Hamburg
Germany Facility # 1 Hannover
Germany Facility # 1 Leipzig Sachsen
Italy Facility # 1 Milano Lombardia
Italy Facility # 1 Roma
Italy Facility # 1 Siena Toscana
Japan Eisai Trail Site 1 Arakawa Tokyo
Japan Eisai Trail Site 1 Katsushika Tokyo
Japan Eisai Trail Site 1 Maebashi Gunma
Japan Eisai Trail Site 1 Minato Tokyo
Japan Eisai Trail Site 2 Minato Tokyo
Japan Eisai Trail Site 1 Musashino Tokyo
Japan Eisai Trail Site 1 Ota Tokyo
Japan Eisai Trail Site 2 Ota Tokyo
Japan Eisai Trail Site 3 Ota Tokyo
Japan Eisai Trail Site 1 Sagamihara Kanagawa
Japan Eisai Trail Site 1 Sapporo Hokkaido
Japan Eisai Trail Site 2 Sapporo Hokkaido
Japan Eisai Trail Site 3 Sapporo Hokkaido
Japan Eisai Trail Site 4 Sapporo Hokkaido
Japan Eisai Trail Site 1 Shibuya Tokyo
Japan Eisai Trail Site 1 Shinagawa Tokyo
Japan Eisai Trail Site 2 Shinagawa Tokyo
Japan Eisai Trail Site 1 Shinjuku Tokyo
Japan Eisai Trail Site 2 Shinjuku Tokyo
Japan Eisai Trail Site 1 Tokorozawa Saitama
Japan Eisai Trail Site 1 Toshima Tokyo
Japan Eisai Trial Site 1 Yokohama Kanagawa
Japan Eisai Trial Site 2 Yokohama Kanagawa
Japan Eisai Trial Site 3 Yokohama Kanagawa
Korea, Republic of Facility # 1 Daegu
Korea, Republic of Facility # 1 Seongnam-si Gyeonggido
Korea, Republic of Facility # 1 Seoul
Korea, Republic of Facility # 3 Seoul
Korea, Republic of Facility # 1 Suwon Gyeonggido
Mexico Facility # 1 Monterrey Nuevo Leon
New Zealand Facility # 1 Auckland
New Zealand Facility # 1 Christchurch South Island
New Zealand Facility # 1 Dunedin South Island
New Zealand Facility # 1 Rotorua
New Zealand Facility # 1 Wellington North Island
Poland Facility # 1 Gdansk
Poland Facility # 1 Katowice
Poland Facility # 1 Ostroda
Poland Facility # 1 Tarnow Malopolskie
Poland Facility # 1 Warszawa Mazowieckie
Poland Facility # 2 Warszawa
Poland Facility # 3 Warszawa
Romania Facility # 1 Brasov
Romania Facility # 1 Bucharest
Romania Facility # 1 Constanta
Romania Facility # 1 Sibiu
Romania Facility # 1 Targu Mures
Spain Facility # 1 Barcelona
Spain Facility # 1 Palma de Mallorca Baleares
Spain Facility # 1 Quart de Poblet Valencia
Spain Facility # 1 Torrejon de Ardoz Madrid
Spain Facility # 1 Valencia
United States Facility # 1 Albuquerque New Mexico
United States Facility # 1 Austin Texas
United States Facility # 2 Austin Texas
United States Facility # 1 Beverly Hills California
United States Facility # 1 Brooklyn New York
United States Facility # 1 Celebration Florida
United States Facility # 1 Chandler Arizona
United States Facility # 2 Chandler Arizona
United States Facility # 1 Colorado Springs Colorado
United States Facility # 1 Dayton Ohio
United States Facility # 1 Elkridge Maryland
United States Facility # 1 Evansville Indiana
United States Facility # 1 Fort Worth Texas
United States Facility # 1 Hialeah Florida
United States Facility # 1 Hickory North Carolina
United States Facility # 1 Homestead Florida
United States Facility # 1 Jacksonville Florida
United States Facility # 1 Kansas City Missouri
United States Facility # 1 Lauderhill Florida
United States Facility # 1 Lincoln Rhode Island
United States Facility # 1 Los Angeles California
United States Facility # 2 Los Angeles California
United States Facility # 1 Maitland Florida
United States Facility # 1 Memphis Tennessee
United States Innovative Clinical Research Inc Miami Florida
United States Facility # 1 Ocala Florida
United States Facility # 1 Oklahoma City Oklahoma
United States Facility # 2 Oklahoma City Oklahoma
United States Facility # 1 Orlando Florida
United States Facility # 1 Oviedo Florida
United States Facility # 1 Pinellas Park Florida
United States Facility # 1 Portland Oregon
United States Facility # 1 Quincy Massachusetts
United States Facility # 1 Redlands California
United States Facility # 1 Rogers Arkansas
United States Facility # 1 Sacramento California
United States Facility # 1 San Angelo Texas
United States Facility # 1 Santa Monica California
United States Facility # 1 Seattle Washington
United States Facility # 1 Tampa Florida
United States Facility # 1 The Villages Florida
United States Facility # 1 Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Eisai Inc.

Countries where clinical trial is conducted

United States,  Canada,  Finland,  Germany,  Italy,  Japan,  Korea, Republic of,  Mexico,  New Zealand,  Poland,  Romania,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6 sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. Baseline and Month 6
Secondary Change From Baseline in sSOL at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1 and 3 sSOL was defined as estimated minutes from time attempted to sleep to sleep onset. Baseline, (mean of 7 nights [approximately Week 1]), Months 1 and 3
Secondary Change From Baseline in Subjective Sleep Efficiency (sSE) at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6 sSE was defined as percentage of subjective total sleep time (sTST) divided by subjective time spent in bed, calculated as the interval from the time the participant reported attempting to sleep until the time participant stopped trying to sleep for the night (operationalized as the time the participant got out of bed for the day), and time spent asleep derived from subjective time spent in bed minus sWASO. Baseline, (mean of 7 nights [approximately Week 1]), Months 1, 3 and 6
Secondary Change From Baseline in Subjective Wake After Sleep Onset (sWASO) at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6 sWASO was defined as sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. Baseline, (mean of 7 nights [approximately Week 1]), Months 1, 3 and 6
Secondary Change From Baseline in sTST at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6 sTST was defined as minutes of sleep from sleep onset to time stopped trying to sleep for the night. Baseline, (mean of 7 nights [approximately Week 1]), Months 1, 3 and 6
Secondary Percentage of Sleep Onset Responders and Sleep Maintenance Responders at Month 6 Sleep onset responder was defined as follows: sSOL at study Baseline was greater than or equal to (>=) 30 minutes and mean sSOL at 6 months was less than or equal to (<=) 20 minutes. Sleep maintenance responder was defined as follows: sWASO at study Baseline was >=60 minutes and mean sWASO at 6 months was <=60 minutes and showed a reduction of greater than (>)10 minutes compared to Study Baseline. Month 6
Secondary Percentage of Sleep Onset Responders and Sleep Maintenance Responders at Month 12 Sleep onset responder was defined as follows: sSOL at study Baseline was >=30 minutes and mean sSOL at 6 months was <=20 minutes. Sleep maintenance responder was defined as follows: sWASO at study Baseline was >=60 minutes and mean sWASO at 6 months was <=60 minutes and showed a reduction of > 10 minutes compared to study Baseline. Month 12
Secondary Change From Baseline in Insomnia Severity Index (ISI) Daytime Functioning Score at Months 1, 3, and 6 The ISI is a 4-7 item, self-report questionnaire assessing the nature, severity, and impact of insomnia. The dimensions evaluated were: 1. severity of sleep onset; 2. sleep maintenance; 3. early morning awakening problems; 4. sleep dissatisfaction; 5. interference of sleep difficulties with daytime functioning; 6. noticeability of the sleep problems by others; and 7. distress caused by the sleep difficulties. A 5-point Likert scale was used to rate each item (from 0=no problem to 4=very severe problem). Daytime functioning score (sum of items 4 to 7) were analyzed. Higher score indicated severe insomnia problem. The total score range for sum of items is 0-16. Baseline, Months 1, 3, and 6
Secondary Change From Baseline in Fatigue Severity Scale (FSS) Total Score at Months 1, 3 and 6 The FSS is a self-reported scale on which participants were instructed to choose a number from 1 to 7 that indicated their degree of agreement with 9 statements about their fatigue where "1" indicates strongly disagree and "7", strongly agree. The FSS total score was the sum of all responses to the 9 questions. Higher total scores and average item scores indicated greater fatigue. Total score range is 9 to 63. Baseline, Months 1, 3 and 6
Secondary Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6 The Sleep Diary was used to assess subjective ratings of morning sleepiness with the following question:
"How sleepy/alert do you feel this morning?" Participants rated their sleepiness/alertness level on a scale from 1 to 9, with 1 being extremely poor (sleepy) and 9 being extremely good (alert). Higher score indicated better outcome.
Baseline, (mean of 7 nights [approximately Week 1]) in placebo-controlled period, Month 1, 3, 6
Secondary Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Active Treatment Period) Baseline, First 7 nights (approximately Week 1) in active treatment period
Secondary Change From Screening in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the First and Second 7 Mornings of the Follow-up Period The Sleep Diary was used to assess subjective ratings of morning sleepiness with the following question:
"How sleepy/alert do you feel this morning?" Participants rated their sleepiness/alertness level on a scale from 1 to 9, with 1 being extremely poor (sleepy) and 9 being extremely good (alert). Higher score indicated better outcome.
Screening, First and second 7 mornings in follow-up period (Week 52 to 54)
Secondary Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at Months 1, 3, 6, 9 and 12 The Sleep Diary was used to assess subjective ratings of morning sleepiness with the following question:
"How sleepy/alert do you feel this morning?" Participants rated their sleepiness/alertness level on a scale from 1 to 9, with 1 being extremely poor (sleepy) and 9 being extremely good (alert). Higher score indicated better outcome.
Baseline, Months 1, 3, 6, 9 and 12
Secondary Rebound Insomnia: Mean sSOL on Each of the First 3 Nights, First 7 Nights, and Last 7 Nights of the Follow-up Period Rebound Insomnia: Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia. sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. First 3 nights, first and Last 7 nights of the follow up period (Week 52 to 54)
Secondary Rebound Insomnia: Mean sWASO on Each of the First 3 Nights, First 7 Nights, and Last 7 Nights of the Follow-up Period Rebound Insomnia: Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia. sWASO was defined as sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. First 3 nights, first and last 7 nights of the follow up period (Week 52 to 54)
Secondary Rebound Insomnia: Percentage of Participants Whose sSOL Was Longer Than at Screening for First 3 Nights of the Follow-up Period, or Whom Mean sSOL Was Longer Than at Screening for First 7 Nights or Last 7 Nights of the Follow-up Period Rebound Insomnia: Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia. sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. First 3 nights, first and last 7 nights of the follow up period (Week 52 to 54)
Secondary Rebound Insomnia: Percentage of Participants Whose sWASO is Higher Than at Screening for First 3 Nights of the Follow-up Period, or Whose Mean sWASO is Higher Than at Screening for the First 7 Nights or Last 7 Nights of the Follow-up Period Rebound Insomnia: Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia. sWASO was defined as sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. First 3 nights, First and Last 7 nights of the follow up period (Week 52 to 54)
Secondary Persistence of Effect: Mean Change From Baseline in sSOL, sWASO, and sTST at Months 3, 6, 9, and 12 Compared to Month 1 sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. sWASO was defined as sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. sTST: minutes of sleep from sleep onset to time stopped trying to sleep for the night. At each month beyond Month 1, the change from Baseline was compared to either the lower bound of the 95% CI (for sTST) or the upper bound of the 95% CI (for sSOL and sWASO) at Month 1. Persistence of efficacy was defined as present if the mean change from Baseline at Month 6 was above the lower bound of the 95% CI at Month 1 for sTST and below the upper bound of the 95% CI at Month 1 for sSOL and sWASO. Baseline, Month 1, 3, 6, 9, 12
Secondary Persistence of Effect: Mean Change From Baseline in sSE at Months 3, 6, 9, and 12 Compared to Month 1 sSE was defined as percentage of sTST per subjective time spent in bed, calculated as the interval from the time the participant reports attempting to sleep until the time the participant stopped trying to sleep for the night (operationalized as the time the participant got out of bed for the day), and time spent asleep derived from subjective time spent in bed minus sWASO. At each month beyond Month 1, the change from Baseline was compared to the lower bound of the 95% CI at Month 1. Persistence of efficacy was defined as present if the mean change from Baseline at Month 6 was above the lower bound of the 95% CI at Month 1 for sSE. Baseline, Months 1, 3, 6, 9, and 12
Secondary Persistence of Effect: Mean Change From Period 2 Baseline (Month 6) in sSOL, sWASO, and sTST at Months 9 and 12 Compared to Month 7 sSOL is defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. sWASO: sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. sTST: minutes of sleep from sleep onset to time stopped trying to sleep for the night. At each month beyond Month 7, the change from Baseline was compared to either the lower bound of the 95% CI for sTST or the upper bound of the 95% CI (for sSOL and sWASO) at Month 7. Persistence of effect was defined as present if the mean change from Baseline at Month 12 was above the lower bound of the 95% CI at Month 7 for sTST and below the upper bound of the 95% CI at Month 7 for sSOL and sWASO. Baseline, Month 7, 9, 12
Secondary Persistence of Effect: Mean Change From Period 2 Baseline (Month 6) in sSE at Months 9 and 12 Compared to Month 7 sSE: percentage of sTST per subjective time spent in bed, calculated as the interval from the time the participant reports attempting to sleep until the time the participant stopped trying to sleep for the night (operationalized as the time the subject got out of bed for the day), and time spent asleep derived from subjective time spent in bed minus sWASO. At each month beyond Month 7, the change from Baseline was compared to the lower bound of the 95% CI for sSE at Month 7. Persistence of effect was defined as present if the mean change from Baseline at Month 12 was above the lower bound of the 95% CI at Month 7 for sSE. Baseline, Month 7, 9, 12
Secondary Persistence of Effect: Mean Change From Study Baseline and Period 2 Baseline (Month 6) in sSOL, sWASO, and sTST at Months 3 and 6 Exposure Compared to Month 1 sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset. sWASO: sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night, operationalized as the time the participant got out of bed for the day. sTST: minutes of sleep from sleep onset to time stopped trying to sleep for the night. At 3 and 6 months of exposure, the change from Baseline was compared to either the lower bound of the 95% CI for sTST or the upper bound of the 95% CI (for sSOL and sWASO) at 1 month of exposure. Persistence of effect was defined as present if the mean change from Baseline at 6 months of exposure was above the lower bound of the 95% CI at 1 month of exposure for sTST and below the upper bound of the 95% CI at 1 month of exposure for sSOL and sWASO. Baseline, Month 1, 3, 6
Secondary Persistence of Effect: Mean Change From Study Baseline and Period 2 Baseline (Month 6) in sSE at Months 3 and 6 Exposure Compared to Month 1 sSE was defined as percentage of sTST per subjective time spent in bed, calculated as the interval from the time the participant reports attempting to sleep until the time the participant stopped trying to sleep for the night (operationalized as the time the participant got out of bed for the day), and time spent asleep derived from subjective time spent in bed minus sWASO. At 3 and 6 months of exposure, the change from Baseline was compared to the lower bound of the 95% CI for sSE at 1 month of exposure. Persistence of effect was defined as present if the mean change from Baseline at 6 months of exposure was above the lower bound of the 95% CI at 1 month of exposure for sSE. Baseline, Month 1, 3, 6
See also
  Status Clinical Trial Phase
Completed NCT00821041 - Internet-based Treatment for Chronic Insomnia Phase 2
Completed NCT03727438 - Provider Supported Self-Help Cognitive Behavioral Therapy for Insomnia (Tele-Self CBTI) N/A
Recruiting NCT03633305 - Optimization of Insomnia Treatment in Primary Care N/A
Completed NCT04616157 - Internet-based Cognitive Behavioral Therapy for Adolescents With Sleep Problems- a Feasibility Trial N/A
Completed NCT03679884 - Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep Phase 3
Completed NCT02839200 - Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder Phase 2
Recruiting NCT04752254 - Investigating Racing Thoughts in Patients With Insomnia Disorder
Completed NCT05541055 - Digital CBT-I for Insomnia Disorder N/A
Completed NCT05558865 - Effectiveness of a Digital Health Application for People With Insomnia Disorder (Somnovia) N/A
Active, not recruiting NCT06393504 - Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
Completed NCT02841709 - Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder Phase 2
Completed NCT03328585 - Telemedicine vs. In-person Delivery of Cognitive Behavioral Treatment of Insomnia: a Mixed Methods Analysis N/A
Recruiting NCT05408078 - Become Your Own SLEEPexpert: a Behavioral Treatment Program for Insomnia in Patients With Psychiatric Disorders N/A
Recruiting NCT05780983 - Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults N/A
Completed NCT03575104 - Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep Phase 3
Not yet recruiting NCT06279286 - Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder Phase 1/Phase 2
Terminated NCT02571595 - A Sleep Program to Improve Sleep Quality in People With HIV N/A
Completed NCT00984698 - A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD) N/A
Recruiting NCT05780177 - Brief Behavioral Treatment for Insomnia in Veterans With Posttraumatic Stress Disorder N/A
Completed NCT05805527 - Evaluating the Validity and Acceptability of a Fully-automated Interview to Diagnose Insomnia Disorder: a Pilot Study